SEC ownership of Scribe Therapeutics, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001853921.

Comparable stake leader

Avoro Capital Advisors LLC

Disclosed value leader

AH Bio Fund II, L.P.

Comparable rows

11/21

Latest evidence

27 Jul 2026

Top shareholders Insider holders Latest transactions
Public ticker
SCTX
Parsed ownership sources
3/4/5 and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
Avoro Capital Advisors LLC
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
11 of 21
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Avoro Capital Advisors LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
27 Jul 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001853921
Issuer location
Alameda, CA

Ownership snapshot

Top shareholders of Scribe Therapeutics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Avoro Capital Advisors LLC
Disclosed value leader
AH Bio Fund II, L.P.
Comparable rows
11/21
Latest evidence
27 Jul 2026
3/4/5 13D/G Lead comparable stake: 16% 10 rows are not safely comparable across share classes. 13D/G row: Avoro Capital Advisors LLC Showing 1-8 of 21 holder rows.

Quick read

Avoro Capital Advisors LLC leads the comparable SEC ownership view at 16%.

11 of 21 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Avoro Capital Advisors LLC's linked filing trail.
Comparable ownership Top 5
Avoro Capital Advisors LLC 16%
RA CAPITAL MANAGEMENT, L.P. 9.6%
ELI LILLY & Co 7.3%
ORBIMED ADVISORS LLC 7.2%
AH Bio Fund II, L.P. 16%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 21 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Avoro Capital Advisors LLC
3/4/5 13D/G
Director, Other*, 10%+ Owner · Aghazadeh Behzad
3/4/5 13D/G
16%
from 13D/G
—
3,103,613 shares
mixed-class rows
 — 24 Jul 2026
RA CAPITAL MANAGEMENT, L.P.
13D/G
13D/G
9.6%
—
1,802,178 shares
 $0 27 Jul 2026
ELI LILLY & Co
3/4/5 13D/G
10%+ Owner
3/4/5 13D/G
7.3%
from 13D/G
—
1,054,828 shares
 — 23 Jul 2026
ORBIMED ADVISORS LLC
3/4/5 13D/G
Director
3/4/5 13D/G
7.2%
from 13D/G
$24,764,427
1,348,825 shares
 — 27 Jul 2026
AH Bio Fund II, L.P.
3/4/5
10%+ Owner
3/4/5
16%
$56,598,831
3,082,725 shares
 — 27 Jul 2026
AH Bio Fund III, L.P.
3/4/5
10%+ Owner
3/4/5
16%
$56,598,831
3,082,725 shares
 — 27 Jul 2026
AH Equity Partners Bio II, L.L.C.
3/4/5
10%+ Owner
3/4/5
16%
$56,598,831
3,082,725 shares
 — 27 Jul 2026
AH Equity Partners Bio III, L.L.C.
3/4/5
10%+ Owner
3/4/5
16%
$56,598,831
3,082,725 shares
 — 27 Jul 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 25 Aug 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 20 reporting-owner rows connected to Scribe Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
20
Largest Forms 3/4/5 holder
Benjamin A. Horowitz
Net 12M change
$0
Latest report
27 Jul 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Benjamin A. Horowitz 10%+ Owner $56,598,831 Market 27 Jul 2026
Marc L. Andreessen 10%+ Owner $56,598,831 Market 27 Jul 2026
AH Bio Fund III, L.P. 10%+ Owner $56,598,831 Market 27 Jul 2026
AH Equity Partners Bio II, L.L.C. 10%+ Owner $56,598,831 Market 27 Jul 2026
AH Bio Fund II, L.P. 10%+ Owner $56,598,831 Market 27 Jul 2026
AH Equity Partners Bio III, L.L.C. 10%+ Owner $56,598,831 Market 27 Jul 2026
ORBIMED ADVISORS LLC Director $24,764,427 Market 27 Jul 2026
OrbiMed Capital GP VIII LLC Director $24,764,427 Market 27 Jul 2026
Carl L. Gordon Director $24,764,427 Market 23 Jul 2026
Jennifer A. Doudna 10%+ Owner Mixed 27 Jul 2026
David Parrot Chief Financial Officer Mixed 23 Jul 2026
James Dean Watson Director Mixed 23 Jul 2026
Benjamin L. Oakes President, CEO, Director, Chairman of the Board Mixed 23 Jul 2026
Avoro Capital Advisors LLC Director, Other*, 10%+ Owner Mixed 24 Jul 2026
Avoro Ventures LLC Director, Other* Mixed 24 Jul 2026
Joshua Bleharski Director Mixed 23 Jul 2026
Behzad Aghazadeh Director, Other*, 10%+ Owner Mixed 24 Jul 2026
Svetlana Lucas Chief Business Officer Mixed 23 Jul 2026
Brett Staahl 10%+ Owner Mixed 23 Jul 2026
ELI LILLY & Co 10%+ Owner Mixed 23 Jul 2026

Recent insider transactions for Scribe Therapeutics, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Aghazadeh Behzad SCTX Common Stock, par value $0.0001 per share Purchase 0.26% 7,905 3,088,888 28 Jul 2026 See footnotes
Aghazadeh Behzad SCTX Common Stock, par value $0.0001 per share Purchase 0.26% 7,905 3,088,888 28 Jul 2026 See footnotes
Behzad Aghazadeh SCTX Common Stock, par value $0.0001 per share Purchase 0.26% 7,905 3,088,888 28 Jul 2026 See footnotes
AH Bio Fund II, L.P. SCTX Common Stock Purchase 16.2% 333,333 2,385,075 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Purchase 16.2% 333,333 2,385,075 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Purchase 16.2% 333,333 2,385,075 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Purchase 16.2% 333,333 2,385,075 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Purchase 16.2% 333,333 2,385,075 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Purchase 16.2% 333,333 2,385,075 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 697,650 697,650 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 697,650 697,650 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 697,650 697,650 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 697,650 697,650 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 697,650 697,650 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 697,650 697,650 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 2,051,742 2,051,742 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 2,051,742 2,051,742 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 2,051,742 2,051,742 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 2,051,742 2,051,742 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 2,051,742 2,051,742 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Common Stock Conversion of derivative security 2,051,742 2,051,742 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Series B Preferred Stock Conversion of derivative security -100% -4,131,344 0 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Series B Preferred Stock Conversion of derivative security -100% -4,131,344 0 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Series B Preferred Stock Conversion of derivative security -100% -4,131,344 0 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Series B Preferred Stock Conversion of derivative security -100% -4,131,344 0 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Series B Preferred Stock Conversion of derivative security -100% -4,131,344 0 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Series B Preferred Stock Conversion of derivative security -100% -4,131,344 0 27 Jul 2026 By AH Bio Fund III, L.P.
AH Bio Fund II, L.P. SCTX Series A Preferred Stock Conversion of derivative security -100% -12,150,003 0 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Series A Preferred Stock Conversion of derivative security -100% -12,150,003 0 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Series A Preferred Stock Conversion of derivative security -100% -12,150,003 0 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Series A Preferred Stock Conversion of derivative security -100% -12,150,003 0 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Series A Preferred Stock Conversion of derivative security -100% -12,150,003 0 27 Jul 2026 By AH Bio Fund II, L.P.
AH Bio Fund II, L.P. SCTX Series A Preferred Stock Conversion of derivative security -100% -12,150,003 0 27 Jul 2026 By AH Bio Fund II, L.P.
Carl L. Gordon SCTX Common Stock Purchase 286.7% 1,000,000 1,348,825 27 Jul 2026 See footnotes
Carl L. Gordon SCTX Common Stock Conversion of derivative security 348,825 348,825 27 Jul 2026 See footnotes
Carl L. Gordon SCTX Series B Preferred Stock Conversion of derivative security -100% -2,065,672 0 27 Jul 2026 See footnotes
Orbimed Advisors Llc SCTX Common Stock Purchase 286.7% 1,000,000 1,348,825 27 Jul 2026 See footnotes
Orbimed Advisors Llc SCTX Common Stock Purchase 286.7% 1,000,000 1,348,825 27 Jul 2026 See footnotes
Orbimed Advisors Llc SCTX Common Stock Conversion of derivative security 348,825 348,825 27 Jul 2026 See footnotes
Orbimed Advisors Llc SCTX Common Stock Conversion of derivative security 348,825 348,825 27 Jul 2026 See footnotes
Orbimed Advisors Llc SCTX Series B Preferred Stock Conversion of derivative security -100% -2,065,672 0 27 Jul 2026 See footnotes
Orbimed Advisors Llc SCTX Series B Preferred Stock Conversion of derivative security -100% -2,065,672 0 27 Jul 2026 See footnotes
Jennifer A. Doudna SCTX Common Stock Conversion of derivative security 2.12% 12,511 603,547 27 Jul 2026 Direct
Jennifer A. Doudna SCTX Series A-1 Preferred Stock Conversion of derivative security -100% -74,088 0 27 Jul 2026 Direct
Aghazadeh Behzad SCTX Common Stock, par value $0.0001 per share Purchase 341.6% 2,383,333 3,080,983 24 Jul 2026 See footnotes
Aghazadeh Behzad SCTX Common Stock, par value $0.0001 per share Purchase 341.6% 2,383,333 3,080,983 24 Jul 2026 See footnotes
Behzad Aghazadeh SCTX Common Stock, par value $0.0001 per share Purchase 341.6% 2,383,333 3,080,983 24 Jul 2026 See footnotes
Brett Staahl SCTX Performance-based Stock Option (Right to Buy) Award 19,385 19,385 23 Jul 2026 Direct
Brett Staahl SCTX Stock Option (Right to Buy) Award 19,385 19,385 23 Jul 2026 Direct
Svetlana Lucas SCTX Common Stock Purchase 3,000 3,000 23 Jul 2026 By Spouse
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .